Research gives support to CBD to help combat schizophrenia

291 0

Continued studies show that the cannabis compound is able to counter schizophrenia

Schizophrenia is a mental-psychotic disorder that drastically alters the perception of reality and thought. Therefore, it is common for people with this condition to suffer from hallucinations, delusions, or paranoid beliefs. Sometimes they also have disorganized thinking and language. Pure cannabidiol (CBD) has been shown to have pharmacotherapeutic efficacy in the treatment of this mental illness, and many studies have supported this.

CBD significantly reduces psychopathological disorders due to its antipsychotic effects, and unlike common medicine, it has fewer adverse effects. Because of this, many patients with schizophrenia use it to alleviate the side effects of common neuroleptic therapy, as well as parkinsonian symptoms. Recent studies on therapeutic strategies for neurodegenerative diseases have focused on the neuroprotective (like slowing ongoing neurodegeneration), anti-inflammatory, and antioxidant properties of cannabinoids, thus considering it not only as a palliative treatment of symptoms but also as a therapeutic approach, delaying symptoms such as dementia.

Researchers from many countries have conducted studies among schizophrenia patients who have undergone treatment with cannabinoids. The research showed that patients who used CBD had a higher density of brain gray matter and had less severe cognitive impairment. Thus, the study concludes that the results support the hypothesis of a lower biological vulnerability, at least in a subgroup of schizophrenic patients and CBD users.

CBD has been shown to offer some unique benefits for this condition that can be added to other treatment targets to maximize the management of the disease. Although much more research remains to be done, many people have achieved a different lifestyle after starting CBD use.